Moody’s downgrades long-term ratings for Eli Lilly
Moody’s Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent expirations the drugmaker faces in coming years.
Health Care
Articles
Study: Substance abuse treatment costly for state
A study at the Center for Health Policy at IUPUI found that 66 cents of every dollar the state spends on services related to substance abuse goes toward health care while only 1 cent goes toward prevention or intervention.
Lilly makes $300M deal for Philadelphia drug company
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
Lilly wins approval of antidepressant Cymbalta for pain
The Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions, which could mean another $500 million in annual sales for Lilly, an analyst estimates.
Indiana health exchange may take page from Utah playbook
In Utah, employers can give each of their workers a specific amount of money to apply toward health insurance. The worker then can use that money to choose from the 66 plans in the health insurance exchange.
Did Lilly get preferential treatment on a disputable billboard ad?
Billboard companies spiked the cancer ad. But Citizens Gas or WellPoint might have gotten a different result.
Elections encourage an arch-conservative
Bill Styring, whose long, wonkish career includes analyzing health reform for Mike Pence, cried last night.
Q&A: Jim Hamilton
Jim Hamilton, an employee-benefits lawyer at Bose McKinney & Evans in Indianapolis, discussed the likelihood of a Republican-controlled U.S. House of Representatives changing or even outright repealing the health care reform law, formally known as the Patient Protection and Affordable Care Act.
Appeals court rejects Lilly over Gemzar patent
Without an appeal, generic drugs are now poised to wipe away most of Lilly’s $750 million in annual U.S. revenue from Gemzar.
Indiana’s life sciences industry sees trouble ahead
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
Ascension aims to cut costs with $10.9M service center
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
Health care firm plans 500 jobs in Indianapolis
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
Zimmer quarterly profit jumps on lower costs
Warsaw-based Orthopedic implant maker Zimmer Holdings Inc. reported net income of $191.1 million, or 96 cents per share. Sales fell 1 percent to $965 million from $975.6 million.
LEADING QUESTIONS: Home-health guru banks on empathy
Jan Roberts pairs numbers and nurturing—further fueled by a fight with breast cancer —to power the city's fifth largest woman-owned business.
Employee ire forces IU to pull wellness survey
Indiana University will no longer ask employees to fill out an online health risk assessment after more than 550 people—many anonymous—attached names to an online petition that said the plan would cause “widespread anger and disillusionment.”
New estimate drops health plan’s cost to Indiana
A new estimate has lowered the expected cost of the federal health care overhaul to Indiana’s state government to perhaps $2.6 billion over the next decade.
Lilly diabetes setbacks may spur shopping for Amylin
Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc.
Analysts: Lilly setbacks might spur shopping spree
CEO John Lechleiter claims Eli Lilly and Co. isn’t interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
Home Health Depot acquires Arcadia subsidiary
The division purchased by Home Health Depot markets and sells home health related items via mail and online. Terms of the deal were not disclosed.
UPDATE: Lilly, others see stock slide after drug rejection
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.